OCRELIZUMAB
Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive B lymphocytes. By depleting these immune cells, it reduces inflammation and immune-mediated damage in the central nervous system, helping slow disease progression in multiple sclerosis (MS).- Relapsing forms of Multiple Sclerosis (RMS), including relapsing-remitting MS - Primary Progressive Multiple Sclerosis (PPMS)
- Initial dose: 300 mg intravenous infusion, followed by a second 300 mg infusion two weeks later - Maintenance dose: 600 mg intravenous infusion every 6 months - Premedication with corticosteroids and antihistamines is recommended to reduce infusion-related reactions.
- Known hypersensitivity to ocrelizumab or any of its components - Active hepatitis B infection - Active, severe infections
- Screen patients for hepatitis B virus before starting treatment - Increased risk of infections, including respiratory and herpes infections - Monitor for infusion-related reactions during and after infusion - Use caution in patients with weakened immune systems - Vaccinations should be completed prior to initiation; live vaccines are not recommended during treatment
- Infusion-related reactions (rash, itching, fever, headache) - Upper and lower respiratory tract infections - Skin infections - Fatigue - Nausea - Back pain
- Other immunosuppressive or immunomodulatory therapies may increase the risk of infections - Live or live-attenuated vaccines should be avoided during and after treatment until B-cell recovery
